The authors concluded that ‘CXCL16 mRNA is a marker for poor prognosis both independently or in combination with CEA mRNA and that it merits further studies.’ Although they were derived using completely different research methods and by setting different goals during the study design, these results partially coincide with our conclusions, as CXCL16 can be considered as an important parameter that can be useful in the detection, staging and prognosis of patients with CRC. This evidence concerns the gene CEACAM5 and colorectal carcinoma.